Skip to main content
Log in

Effects of nafamostat mesilate, somatostatin, and glucagon on caerulein-induced acute pancreatitis in rats

  • Original Articles
  • Published:
Journal of Hepato-Biliary-Pancreatic Surgery

Abstract

The inhibitory effects of somatostatin (SMS) and glucagon (Gn) on acute pancreatitis were evaluated in an experimental acute pancreatitis model in male Wistar rats. The effects of these agents were compared with those of nafamostat mesilate (NM). The acute pancreatitis was induced by four serial subcutaneous injections of caerulein. The rats were divided into four groups. The first group (n=28) received SMS daily, the second group (n=28) received Gn daily, and the third group (n=28) received NM daily after the first injection of caerulein. The fourth group (n=42) received caerulein alone and served as the control group. Animals were sacrificed 4, 6, 8, 12, and 24 h, and 3 and 7 days after the first administration of caerulein and the degree of severity of the acute pancreatitis was evaluated by serial morphological and histological examinations of pancreatic tissues, as well as in terms of the serum concentrations of amylase and lipase. The characteristic findings of acute pancreatitis in the animals of all groups treated with SMS, Gn, or NM were markedly attenuated at all time points after the treatments compared with findings in the controls (caerulein alone) in terms of wet weight of pancreas, serum concentrations of amylase and lipase, formation of intracellular vacuoles in acinar cells, interstitial edema, and infiltration of an inflammatory cell component. The inhibitory effects of SMS, Gn, and NM on acute pancreatitis were similar at the doses used. These results suggest that SMS and Gn are as useful as NM, they may be of value for the treatment of acute pancreatitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Seinberg WM, Schlesselman SE (1987) Treatment of acute pancreatitis. Comparison of animal and human studies. Gastroenterology 93:1420–1427.

    Google Scholar 

  2. Banks PA (1994) Acute pancreatitis: Medical and surgical management. Am J Gastroenterol 189:S78-S85

    Google Scholar 

  3. Kataoka K, Tachibana I, Imoto M, Kashima T (1993) Role of CCK in deterioration of acute pancreatitis (in Japanese). Tan To Sui (Bihary Tract and Pancreas) 14:853–859.

    Google Scholar 

  4. Lampel M, Kern HF (1977) Acute interstitial pancreatitis in the rat induced by excessive doses of a pancreatic secretagogue. Virchows Arch [A] 373:97–117

    Article  CAS  Google Scholar 

  5. Tani S, Otsuki M, Fujii M, Nakamura T, Oka T, Itoh H, Baba S (1986) Time course of biochemical and histologic alterations in experimental acute pancreatitis in rats induced by subcutaneous injections of caerulein. J Jpn Pancr Soc 1:9–15

    Google Scholar 

  6. Steer ML, Meldolesi J (1987) The cell biology of experimental pancreatitis. New Engl J Med 316:144–150

    Article  CAS  PubMed  Google Scholar 

  7. Lankisch PG, Koop H, Winckler K, Folish UR, Creutzferdt W (1977) Somatostatin therapy of acute experimental pancreatitis. Gut 18:713–716

    CAS  PubMed  Google Scholar 

  8. Van Ooijen B, Tinga CJ, Kort WJ, Zijlstra FJ, Lamberts SW, Wilson JH (1992) Effects of long-acting somatostatin analog (SMS201-995) on eucosanoid synthesis and survival in rats with acute pancreatitis. Dig Dis Sci 37:1434–1440

    Article  PubMed  Google Scholar 

  9. Rohr G, Keim V, Usadel KH (1986) Prevention of experimental pancreatitis by somatostatin. Klin Wochenschr 64:90–92

    CAS  PubMed  Google Scholar 

  10. Murayama KM, Drew JB, Joehl RJ (1990) Does somatostatin analogue prevent experimental acute pancreatitis? Arch Surg 125:1570–1572

    CAS  PubMed  Google Scholar 

  11. Waterwoth MW, Barbezat GO, Hickman R, Terblanche J (1976) A controlled trial of glucagon in experimental pancreatitis. Br J Surg 63:617–620

    Google Scholar 

  12. Gjørup I, Roikjær O, Andersen B, Burcharth RJ, Hovendal C, Pedersen SA, Christiansen P, Wara P, Andersen JC, Balslev I (1992) A double-blind multicenter trial of somatostatin in the treatment of acute pancreatitis. Surg Gynecol Obstet 175:397–400

    PubMed  Google Scholar 

  13. Amico DD, Favia G, Biasiato M, Casaccia M, Falcone F, Fersini M, Marrano D, Naporitano F, Oriviero S, Rodolico A (1990) The use of somatostatin in acute pancreatitis — results of a multicenter trial. Hepatogastroenterology 37:92–98

    PubMed  Google Scholar 

  14. Boden G, Sivitz MC, Owen OE (1975) Somatostatin suppresses secretin and pancreatic exocrine secretion. Science 190:163–165

    CAS  PubMed  Google Scholar 

  15. Raptis S, Schlegel W, Lehemann E, Dollinger HC (1978) Effects of somatostatin on the exocrine pancreas and the release of duodenal hormones. Metab Clin Exp 27:1321–1328

    CAS  PubMed  Google Scholar 

  16. Owyang C, Louie DS, Tatum D (1986) Feedback regulation of pancreatic enzyme secretion. Suppression of cholecystokinin release by trypsin. J Clin Invest 77:2042–2047

    Article  CAS  PubMed  Google Scholar 

  17. Louie DS, May D, Miller P, Owyang C (1986) Cholecystokinin mediates feedback regulation of pancreatic enzyme sectretion in rats. Am J Physiol 250:G252-G259

    CAS  PubMed  Google Scholar 

  18. Rausch U, Adler G, Weidenbach H, Rudolff D, Koop I, Kern HF (1987) Stimulation of pancreatic secretory process in the rat by low-molecular weight proteinase inhibitor. I. Dose-response study on enzyme content and secretion, cholecystokinin release and pancreatic fine structure. Cell Tissue Res 247:187–193

    Article  CAS  PubMed  Google Scholar 

  19. Fuji S, Hitomi Y (1981) New synthetic inhibitors of Clr, Cl esterase, thrombin, plasmin, kallikrein and trypsin. Biochem Biophys Acta 661:342–345

    Google Scholar 

  20. Ikeda M, Takeuchi T (1991) How are protease inhibitors regarded in the treatment of pancreatitis in foreign countries? (in Japanese) Tan To Sui (Biliary Tract and Pancreas) 12:893–898

    Google Scholar 

  21. Wisner JR, Ozawa S, Renner IG (1989) The effect of nafamostat mesilate (FUT-175) on caerulein-induced acute pancreatitis in the rat. Int J Pancreatol 14:383–390

    Google Scholar 

  22. Suzuki M, Frey CF, Isaji S (1989) Effect of a new synthetic protease inhibitor on experimental acute pancreatitis in mice. Pancreas 4:644

    Google Scholar 

  23. Baxter JN, Jenkis SA, Day DW (1985) Effects of somatostatin and long-acting somatostatin analogue on the prevention and treatment of experimentally induced acute pancreatitis in the rat. Br J Surg 72:382–385

    CAS  PubMed  Google Scholar 

  24. Dyck WP, Texter EC, Lasater JM, Hightower NC Jr (1970) Influence of glucagon on pancreatic exocrine secretion in man. Gastroenterology 58:532–539

    CAS  PubMed  Google Scholar 

  25. Lankisch PG, Winckler K, Borkermann M (1974) The influence of glucagon in experimental pancreatitis in rats. Scand J Gastroenterol 9:725–729

    CAS  PubMed  Google Scholar 

  26. Konturek SJ, Tasler J, Obtulowiez W (1974) Characteristics of inhibition of pancreatic secretion by glucagon. Digestion 10:138–149

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

About this article

Cite this article

Mori, K., Marugami, Y., Sakurai, Y. et al. Effects of nafamostat mesilate, somatostatin, and glucagon on caerulein-induced acute pancreatitis in rats. J Hep Bil Pancr Surg 3, 297–303 (1996). https://doi.org/10.1007/BF02391031

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02391031

Key words

Navigation